



Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Breast Committee

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair:Priyanka Sharma, MD
 Executive Officer:..... Anne Chiang, MD, PhD
 Statisticians:Allison Meisner, PhD
Shay Bellasea, MS
 Danika Lew, MA
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging:..... TBD
 Pathology:.....David L. Rimm, MD, PhD
 Early Therapeutics:Stephanie L. Graff, MD

Designates

Adolescent & Young Adults: Erin Elizabeth Roesch, MD
 Cancer Control Liaisons: Mariya Rozenblit, MD (Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
Helen K. Chew, MD (Symptom Management)
 NCORP Representative:Philip E. Lammers, MD
 Veterans Affairs:Sarah V. Colonna, MD
 Data Coordinators:Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Larry G. Kaye
 Kevin Moralda, BS
 Oncology Research Professionals: Cameo Windham, BSN, RN
 Patient Advocates: Roberta A. Albany
 Jamie LaScala
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Sr. Protocol Project Manager: Chris Kippola, BS
 Clinical Trials Program Manager:Sharon Palmer

Time/Location

Friday, May 1, 2026 4:30 p.m. - 6:30 p.m.
 Room: Seacliff BCD (Bay Level)

Agenda

4:30- 4:35 pm	Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)
Robert Livingston Lecture	
4:35 - 5:05 pm	Circulating Tumor-DNA to Guide Therapies: The Breast is Yet to Come - Ben Ho Park, MD, PhD Director, Vanderbilt-Ingram Cancer Center Benjamin F. Byrd, Jr. Chair in Oncology Professor of Medicine, Division of Hem / Onc Vanderbilt University Medical Center
5:05 - 5:10 pm	Q&A
Committee Business and Updates	
5:10 - 5:20 pm	Publication update – Allison Meisner, PhD
5:20 - 5:30 pm	Patient Advocate update – Roberta Albany and Jamie LaScala
5:30 - 5:40 pm	Translational Medicine Sub-Committee update - Alastair Thompson, MD and Andrew K. Godwin, PhD
5:40 - 6:15 pm	Review of open and upcoming CTSU trials
6:15 - 6:30 pm	Reports from Committee Liaisons NCORP: Philip Lammers, MD Symptom Management: Lynn Henry, MD, PhD Radiotherapy: Reshma Jagsi, MD, PhD Surgery: Joshua Mammen, MD Cancer Care Delivery: Dawn Hershman, MD Prevention: Banu Arun, MD Theranostics Subcommittee: Shane Stecklein, MD, PhD & Joanne Mortimer, MD Early Therapeutics: Stephanie Graff, MD
6:30 pm	Closing Comments and Adjour

NCI Approved Concepts

S2511, “Randomized Phase III trial of multimodality therapy versus standard of care systemic therapy in HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer with response to initial chemotherapy.” Approved: 7/17/25.

Breast Committee

Active Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Puztai. Activated: 10/30/23.

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 7/21/23.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 1/6/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 5/30/18.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 6/7/21.

Closed Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Puztai and Mammen. Activated: 11/15/16; Permanently closed: 6/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^{A3} Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Puztai. Activated: 9/4/13; Permanently closed: 5/1/19.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 9/12/18. Permanently closed: 7/1/24.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20. Permanently closed: 4/7/25.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 2/7/14; Permanently closed: 7/1/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 2/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 4/2/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 5/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 6/26/15; Permanently closed: 4/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 3/12/19; Permanently closed: 7/1/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 4/13/17; Permanently closed: 12/2/22.

Breast Committee

Active Symptom Management and Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17. Arms 1 and 2 permanently closed to accrual: 11/1/24.

Closed Symptom Management and Survivorship Study

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Study

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 7/16/18.

Closed Prevention, Screening and Surveillance Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 9/1/20. Permanently closed: 6/14/24.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 7/6/17. Closed to accrual: 12/20/24.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 1/13/17; Permanently closed: 3/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15; Permanently closed: 12/30/22.

Clinical Trials Partnerships (CTP)

Developing Studies

21CTP.BREAST01, "MONITOR (Molecular Assessment and Identification of ctDNA and Optimizing Treatment for HR-positive, Her2-negative Metastatic Breast Cancer)". Drs. Kalinsky, Bhawe, and Ali.

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S0221 Long-term follow-up of S0221, comparing alternative dose schedules of anthracycline/taxane therapy in early breast cancer. Ali A, Barlow WE, Moore HCF, Hobday TJ, Isaacs C, Salim M, Albain KS, Chew HK, Burton GV, Srkalovic G, McGregor BA, Flaherty LE, Lew DL, Gralow JR, Hortobagyi GN, Sharma P, Puzstai L, Budd GT. *JNCI Cancer Spectr.* 2026 Mar 14:pkag024. doi: 10.1093/jncics/pkag024. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41832961/>

S0500 Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis. Wolfgang Janni, Thomas W P Friedl, Tracy C Yab, Francois-Clément Bidard, Massimo Cristofanilli, Daniel F Hayes, Michail Ignatiadis, Meredith M Regan, Catherine Alix-Panabieres, William E Barlow, Carlos Caldas, Lisa A Carey, Luc Dirix, Tanja Fehm, Jose A Garcia-Saenz, Paola Gazzaniga, Daniele Generali, Lorenzo Gerratana, Rafael Gisbert-Criado, William Jacot, Zefeji Jiang, Simon A Joosse, Evi Lianidou, Rafael López López, Mark J M Magbanua, Luis Manso, Dimitris Mavroudis, Volkmar Müller, Elisabetta Munzone, Klaus Pantel, Jean-Yves Pierga, Brigitte Rack, Sabine Riethdorf, Hope S Rugo, Kostandinos Sideras, Stefan Sleijfer, Jeffrey Smerage, Justin Stebbing, Leon W M M Terstappen, Jose Vidal-Martínez, Markus Wallwiener, Karthik V Giridhar, Minetta C Liu. *Clin Cancer Res.* 2025 Jun 3;31(11):2196-2209. doi: 10.1158/1078-0432.CCR-24-3108. <https://pubmed.ncbi.nlm.nih.gov/40100138/>

S1007 Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, Priya Rastogi, Anne F Schott, Rick Baehner, Priyanka Sharma, Debasish Tripathy, Lajos Pusztai, Gabriel

Breast Committee

N Hortobagyi, Kevin Kalinsky, N Lynn Henry. *JAMA Oncol.* 2025 Dec 11:e255220. doi: 10.1001/jamaoncol.2025.5220. Online ahead of print. [see also Symptom Management & Survivorship Committee] <https://pubmed.ncbi.nlm.nih.gov/41379459>

A221405 Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial. Fedro A Peccatori, Samuel M Niman, Ann H Partridge, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Satersdal, Judith R Kroep, Karen Gelmon, Frederic Amant, Audrey Mailliez, Halle C F Moore, Manuel Ruiz-Borrego, Janice M Walshe, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Christobel Saunders, Vesna Bjelic-Radicic, Snezana Susnjar, Fatima Cardoso, Natalie J Klar, Teresa Ferreiro, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani, Hatem A Azim Jr; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. *Journal of Clinical Oncology*, 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9. [see also Symptom Management & Survivorship Committee] <https://pubmed.ncbi.nlm.nih.gov/40632989/>

C40601/Others Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). A Fernandez-Martinez, M Tanioka, S G Ahn, P Zagami, T Pascual, M Rediti, G Tang, K A Hoadley, D Venet, N U Rashid, P A Spears, S Di Cosimo, E de Azambuja, A Choudhury, P Rastogi, M N Islam, J Cortes, A Lombart-Cussac, S M Swain, C Sotiriou, A Prat, C M Perou, L A Carey. *Ann Oncol.* 2025 Apr;36(4):403-413. doi: 10.1016/j.annonc.2024.12.010. Epub 2024 Dec 18. NIHMS2052322. <https://pubmed.ncbi.nlm.nih.gov/39706338/>

Submitted Manuscripts

S1007 Recurrence Score Gene Group Components and Outcomes in the RxPONDER Trial (SWOG S1007). Y Abdou, J Hoag, W Barlow, K Albain, J Gralow, J Gralow, F Meric-Bernstam, D Hayes, N Lin, E Perez, L Goldstein, S Chia, S Dhesy-Thind, P Rastogi, A Schott, J Racz, D Tripathy, G Hortobagyi, L Pusztai, P Sharma, K Kalinsky. Submitted 2025.

S1007 Ovarian Reserve as a Measure of Adjuvant Chemotherapy Benefit in Women with Hormone Receptor Positive (HR+), HER2-negative, Node-positive Breast Cancer in SWOG S1007 (RxPONDER). Kalinsky K, Barlow W, Puri R, Mitra A, Home T, Gralow J, Albain K, Hayes D, Delaloge S, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstein F, Sharma P, Pusztai L, Thompson A, Pathak H, Godwin A. Submitted 2025.

S1706 Toxicity in a Randomized Trial Comparing Radiotherapy +/- Olaparib for Inflammatory Breast Cancer. Reshma Jaggi, Allison Meisner, Pavani Chalasani, William E. Barlow, Jennifer R. Bellon, Norah N. Lynn Henry, Danika Lew, Martha M. Matuszak, Jean M. Moran, Lori J. Pierce, Eileen Rakovitch, Stephanie J. Reyes, Corey Speers, Joseph M. Unger, Julia R. White, Wendy A. Woodward, Richard Cedric Zellars, Lajos Pusztai, Priyanka Sharma. Submitted 2025. [see also Symptom Management & Survivorship Committee]

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	A012301	EA1211	MA39
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	12	-	-	-	-
Banner University Medical Center - Tucson	1	-	3	-	-	-	-	-	-
Baptist Mem Health Care/Mid So Minority Underserved NCORP	3	-	6	13	-	-	-	2	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	3	8	2	2	2	-	3
Boston Medical Center	-	-	-	1	6	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	-	-	2	-	2
Cancer Research Consortium of West Michigan NCORP	1	-	3	16	-	-	-	-	-
Cancer Research for the Ozarks NCORP	3	-	-	12	1	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	1	12	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	2	5	19	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	7	4	1	1	1	-	-
City of Hope Comprehensive Cancer Center	-	-	3	18	-	-	-	-	1
Columbia University Minority Underserved NCORP	4	-	2	1	-	-	-	-	-
CommonSpirit Health Research Institute	2	-	1	11	-	-	-	-	2
Dayton NCI Community Oncology Research Program	-	1	-	-	-	-	-	-	-
Desert Regional Medical Center	1	-	-	-	-	-	-	-	1
Essentia Health NCI Community Oncology Research Program	-	-	1	2	1	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	5	-	-	11	-	11	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	1	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	2	9	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	3	9	-	1	-	1	-
Hartford Hospital	-	-	-	4	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	12	-	-	-	1	-
Heartland Cancer Research NCORP	4	-	8	28	1	-	-	-	-
Henry Ford Hospital	2	-	3	11	2	8	2	-	3
Houston Methodist Hospital	-	-	-	-	2	2	-	-	3
Instituto Nacional De Cancerologia de Mexico	-	-	-	15	-	-	-	-	-
Intermountain Medical Center	-	-	-	12	-	-	4	-	1
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	24	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	1	2	1	-	7	-	-
Loma Linda University Medical Center	-	-	-	4	-	-	-	-	-
Loyola University Medical Center	-	-	3	1	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	1	-	3	-	-	1	-	-	8
Miami Cancer Institute	-	-	-	5	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	4	-	6	21	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	9	-	-	1	-	-
Mount Sinai Hospital	-	-	2	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	7	13	-	-	-	-	-
New Mexico Minority Underserved NCORP	6	1	-	-	-	1	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2206	S2212	A011801	A012103	A012301	EA1211	MA39
Northwell Health NCORP	-	1	3	5	-	-	-	-	-
Northwestern University LAPS	1	2	1	33	1	1	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	10	-	-	-	-	-
Oregon Health and Science University	-	-	4	2	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	2	-	13	25	-	-	-	-	4
Regents of the University of Michigan	3	-	4	9	2	3	-	-	14
Rhode Island Hospital	-	-	-	2	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	4	-	-
South Sound Care Foundation	-	-	6	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	8	46	1	-	-	-	-
Sutter Cancer Research Consortium	-	-	3	11	3	-	-	-	-
The Don and Sybil Harrington Cancer Center	3	-	-	-	3	-	4	-	-
The West Clinic - Wolf River	-	-	-	25	-	-	-	-	-
Tufts Medical Center	-	-	-	1	-	-	1	-	-
UC Davis Comprehensive Cancer Center LAPS	7	-	-	-	-	3	10	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	3	-	2	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	2
UPMC Hillman Cancer Center LAPS	1	-	6	8	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	1	-	-	-	7
U of Alabama at Birmingham / Deep So Research Consortium LAPS	-	2	-	6	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	4	2	4	-	-	-
University of Colorado Cancer Center LAPS	1	-	3	4	1	-	5	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	9	18	1	3	10	-	8
University of Kentucky/Markey Cancer Center	-	-	1	1	-	-	-	-	-
University of Mississippi Medical Center	-	-	-	1	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	3	-	5	1	-	-
University of Oklahoma Health Sciences Center LAPS	1	-	3	6	-	-	-	1	-
University of Rochester LAPS	1	-	-	1	-	-	4	-	-
University of Texas Health Science Center at San Antonio	-	4	8	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	1	2	1	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	5	-	-	-	2	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	2	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	5	12	2	-	-	4	4
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	1
Wisconsin NCI Community Oncology Research Program	1	-	1	7	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	32	3	-	-	-	-
ALLIANCE	18	7	39	202	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-	-
ECOG-ACRIN	11	3	58	176	-	-	-	-	-
NRG	48	-	34	118	-	-	-	-	-
Total	160	28	290	1,076	55	46	58	9	66

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR008	NRGBR009
Arnot Ogden Medical Center/Falck Cancer Center	1	-	-
Banner MD Anderson Cancer Center	-	-	-
Banner University Medical Center - Tucson	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	1	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	3
Boston Medical Center	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-
Cedars-Sinai Medical Center	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-
Columbia University Minority Underserved NCORP	-	-	-
CommonSpirit Health Research Institute	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-
Desert Regional Medical Center	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	7
Georgia Cares Minority Underserved NCORP	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-
Gulf South Minority Underserved NCORP	-	-	-
Hartford Hospital	-	-	-
Hawaii Minority Underserved NCORP	1	-	-
Heartland Cancer Research NCORP	-	-	1
Henry Ford Hospital	-	-	2
Houston Methodist Hospital	2	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	3
Intermountain Medical Center	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-
Lahey Hospital and Medical Center	-	-	-
Loma Linda University Medical Center	-	-	1
Loyola University Medical Center	-	-	1
Medical University of South Carolina Minority Underserved NCORP	-	-	-
Miami Cancer Institute	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-
Montana Cancer Consortium NCORP	-	-	-
Mount Sinai Hospital	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-
New Mexico Minority Underserved NCORP	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGBR007	NRGBR008	NRGBR009
Northwell Health NCORP	2	-	-
Northwestern University LAPS	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-
Oregon Health and Science University	1	-	-
Pacific Cancer Research Consortium NCORP	-	-	-
Regents of the University of Michigan	-	-	-
Rhode Island Hospital	-	-	-
Salem Hospital	-	-	-
South Sound Care Foundation	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-
Sutter Cancer Research Consortium	6	-	1
The Don and Sybil Harrington Cancer Center	-	-	5
The West Clinic - Wolf River	-	-	2
Tufts Medical Center	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-
UC San Diego Moores Cancer Center	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-
U of Alabama at Birmingham / Deep S Research Consortium LAPS	-	-	-
University of Arkansas for Medical Sciences	-	-	-
University of Colorado Cancer Center LAPS	3	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	3	-	2
University of Kentucky/Markey Cancer Center	-	-	-
University of Mississippi Medical Center	-	-	-
University of Nebraska Medical Center	1	-	2
University of Oklahoma Health Sciences Center LAPS	-	-	-
University of Rochester LAPS	-	-	-
University of Texas Health Science Center at San Antonio	10	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1
Western States Cancer Research NCORP	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-
ALLIANCE	-	-	-
CCTG	-	-	-
ECOG-ACRIN	-	-	-
NRG	-	-	-
Total	31	1	31

